Drug

NPI 2358 clinical trials

Also written Plinabulin, NPI-2358 and BPI-2358.

studies test it: 14
open now: 2
in phase 3: 4
first study started: 2006

Keep track of what changes. Save the NPI 2358 studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.

Watch these studies

How studies write it

Studies that test it under each name

Studies by the year they started

14 studies that test it; most in 2017 (3)

Studies that test NPI 2358, by start year
Year	Studies
2006	1
2008	1
2015	1
2016	1
2017	3
2018	2
2019	1
2021	2
2024	1
2026	1

By phase

A phase 1/2 study counts in both.

Phase 1: 6
Phase 2: 8
Phase 3: 4

What it is tested for

Each study’s main condition, where its own words name it.

Neutropenia: 4
Carcinoma, Non-Small-Cell Lung: 4
Multiple Myeloma: 1
Lung Neoplasms: 1
Lymphoma: 1
Small Cell Lung Carcinoma: 1
Urinary Bladder Neoplasms: 1

Who runs them

Industry 8 · Other 6

BeyondSpring Pharmaceuticals Inc. (6) · Nereus Pharmaceuticals, Inc. (2) · Memorial Sloan Kettering Cancer Center (1) · Salma Sabbour (1) · Lyudmila Bazhenova, M.D. (1) · Xiaorong Dong (1) · M.D. Anderson Cancer Center (1) · University of Washington (1)

Often tested with

Tested in the same studies.

Nivolumab (3) · Docetaxel (2) · Ipilimumab (1) · Pegfilgrastim (1) · Pembrolizumab (1) · Etoposide (1) · Platinum (1)

Studies

Open first, then newest update. How each study uses NPI 2358 is read from its arms, and is right about nine times in ten.

Testing it · 14

Codes

What other systems call NPI 2358 · ClinicalTrials.gg INT004981

MeSH (NLM) C514351NPI 2358One source ClinicalTrials.gov

System	Code	Name there	Checked by
MeSH (NLM)	C514351	NPI 2358	One source ClinicalTrials.gov

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.